Scinai Immunotherapeutics
Elad Mark currently serves as the Chief Operating Officer at BiondVax Pharmaceuticals Ltd., where responsibilities include overseeing diverse business operations, implementing strategies for growth, and assisting the CEO in fundraising. Previously, Elad held the position of Director/Principal Engineer at Antero Engineering, focusing on providing technical solutions in the Life Sciences sector. Prior to that, roles at Novartis encompassed Technical Project Manager and Area Lead Process, where projects were completed according to stringent GMP and safety standards. Elad's earlier experience at Biopharmax Group Ltd. featured leadership in the engineering department and various project management roles, including the management of a significant insulin manufacturing facility. Educational qualifications include a Bachelor of Science in Mechanical and System Engineering from Afeka Tel Aviv Academic College of Engineering and a Master of Business Administration from The Open University of Israel.
This person is not in any offices
Scinai Immunotherapeutics
1 followers
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases. With a state-of-the-art facility for biopharmaceutical product development and manufacturing and highly experienced pharmaceutical industry leadership, Scinai offers end-to-end boutique CDMO services in parallel to developing its own pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized VHH antibody (NanoAb) pipeline targeting diseases with large unmet medical needs. Company website: www.scinai.com